Susceptibility of Multidrug-Resistant
Humans
Anti-Bacterial Agents
/ pharmacology
Ceftazidime
/ pharmacology
Pseudomonas aeruginosa
Klebsiella pneumoniae
Escherichia coli
Cross-Sectional Studies
Pseudomonas Infections
/ drug therapy
Microbial Sensitivity Tests
Cephalosporins
/ pharmacology
Tazobactam
/ pharmacology
Drug Combinations
beta-Lactamase Inhibitors
/ pharmacology
Carbapenems
/ pharmacology
Imipenem
/ pharmacology
beta-lactam/beta-lactamase-inhibitor combination
carbapenem resistance
colistin
Journal
Microbial drug resistance (Larchmont, N.Y.)
ISSN: 1931-8448
Titre abrégé: Microb Drug Resist
Pays: United States
ID NLM: 9508567
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
medline:
11
4
2023
pubmed:
10
1
2023
entrez:
9
1
2023
Statut:
ppublish
Résumé
This cross-sectional in-vitro resistance surveillance study involving 10 medical laboratories was conducted in 2018. Each study site was asked to collect 30 consecutive nonduplicate isolates per species from hospitalized patients with documented infections. Minimum inhibitory concentrations were determined at a central laboratory. European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints were used for interpretation. A total of 860 isolates were collected, including 298
Identifiants
pubmed: 36622756
doi: 10.1089/mdr.2022.0175
doi:
Substances chimiques
Anti-Bacterial Agents
0
avibactam, ceftazidime drug combination
0
Ceftazidime
9M416Z9QNR
ceftolozane
37A4IES95Q
relebactam
Y1MYA2UHFL
Cephalosporins
0
ceftolozane, tazobactam drug combination
0
Tazobactam
SE10G96M8W
Drug Combinations
0
beta-Lactamase Inhibitors
0
Carbapenems
0
Imipenem
71OTZ9ZE0A
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
138-144Investigateurs
Karsten Becker
(K)
Sören Becker
(S)
Thomas Demant
(T)
Ulrich Eigner
(U)
Reinhard Hoffmann
(R)
Colin MacKenzie
(C)
Holger Rohde
(H)
Hannes Stappmanns
(H)